Gluetacs Therapeutics was selected for the Huayi 2024 China Biopharmaceutical Technology Innovation Value List Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential

ON：2024-09-11 TAGS：GLUETACS THERAPEUTICS

Recently, the grand ceremony of the “2024 China Biopharmaceutical Technology Innovation Value List” by Huayi was held in Shanghai, where Gluetacs Therapeutics was selected for the Huayi 2024 China Biopharmaceutical Technology Innovation Value List Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential.

The “2024 China Biopharmaceutical Technology Innovation Value List” aims to identify innovative companies in the biopharma field that truly have industry influence and leadership.

all pictures from Huayi 2024 China Biopharmaceutical Technology Innovation Value

The list is divided into three series: Corporate Value List, Financial Institutions List, and Park List. The Corporate Value List is further divided into 10 major areas: small molecule innovative drugs, biologics, traditional Chinese medicine, vaccines, cell and gene therapy, innovative medical devices, in vitro diagnostics, consumer healthcare, digital health, and CXO. Based on the quantitative growth evaluation criteria for enterprises that Huayi Research Institute has refined over the years, combined with basic processes such as questionnaire surveys, corporate interviews, data analysis, and verification, the review panel standardizes and quantifies the dynamic data of shortlisted biopharma companies and institutions, thereby selecting the enterprises with significant industry value for the year and forming an objective third-party evaluation list within the industry.

The small molecule innovative drug list primarily focuses on companies with pipelines of small molecule innovative drugs that have significant clinical value and are relatively advanced in research and development. The listed companies generally place a high emphasis on R&D investment, continuously promoting innovation in small molecule drugs. Besides paying attention to the domestic market, they are also actively expanding into international markets. Being awarded the Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential highlights the industry experts’ high recognition of Gluetacs Therapeutics’ growth potential and comprehensive strength in the field of small molecule innovative drug R&D.